A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 over 52 Weeks in Participants with Early Alzheimer’s Disease.
Apply to Participate
If you are interested in participating in this study, please complete the following preliminary qualification form.
We will follow-up with you after we have received your submission.